PE20061419A1 - Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) - Google Patents
Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap)Info
- Publication number
- PE20061419A1 PE20061419A1 PE2006000473A PE2006000473A PE20061419A1 PE 20061419 A1 PE20061419 A1 PE 20061419A1 PE 2006000473 A PE2006000473 A PE 2006000473A PE 2006000473 A PE2006000473 A PE 2006000473A PE 20061419 A1 PE20061419 A1 PE 20061419A1
- Authority
- PE
- Peru
- Prior art keywords
- lys
- ala
- cys
- gln
- val
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 title abstract 2
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 title 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 title 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 title 1
- 108060000200 adenylate cyclase Proteins 0.000 title 1
- 102000030621 adenylate cyclase Human genes 0.000 title 1
- 229940126513 cyclase activator Drugs 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
REFERIDA A UN PEPTIDO DE FORMULA (I), DONDE A1 ES His, Ala; A2 ES Ser, Thr, Ala; A3 ES Asp, Glu; A4 ES Ala, Gly; A5 ES Val, Ile; A8 ES Asp, Glu, Ala; A9 ES Gln, Asn, Ser, Ala; A11 ES Thr, Ser; A12 ES Arg, Lys; A13 ES Leu, Tyr; A15 ES Lys, Ala; A16 ES Gln, Ala; A17 ES ES Val, Met, Leu, ENTRE OTROS; A19 ES Ala, Val, Gly, Lys, ENTRE OTROS; A20 ES Lys, His; A21 ES Lys, His, Ala; A24 ES Gln, Asn, Ala; A25 ES Ser, Asp, Thr, Ala; A26 ES Ile, Val, Leu, ENTRE OTROS; A27 ES CUALQUIER AMINOACIDO; A28 ES Gln, Asn, Gly, ENTRE OTROS; A29 ES Lys, Gly, Arg, ENTRE OTROS; A30 ES CUALQUIER AMINOACIDO O ESTA DELETEADO; A31 ES Tyr, Thr, Cys O ESTA DELETEADO; A32 ES Lys, Cys, Lys-X, ENTRE OTROS; A33 ES Gln, Lys, Cys, ENTRE OTROS; A34 ES Arg, Cys, Lys-X, ENTRE OTROS; A35 ES Val, Cys, Lys, ENTRE OTROS; A36 ES Lys, Cys, Lys-X, ENTRE OTROS; A37 ES Asn, Lys, Cys, ENTRE OTROS; A38 ES Lys, Cys, Lys-X, ENTRE OTROS; A39 ES Lys, Cys, Lys-X, ENTRE OTROS; lYS-X ES Lys MODIFICADO EN Ne CON UN ACIDO GRASO; Z1 ES H, CH3(CH2)nCO, ENTRE OTROS; n ES UN ENTERO DE 0 A 22; Z2 ES OH, NH2, NH-(CH2)5COOH, ENTRE OTROS. DICHO PEPTIDO SON AGONISTAS DEL RECEPTOR VPAC2 Y SON UTILES EN LA DISMINUCION DE LA SECRECION DE INSULINA ENDOGENA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67886005P | 2005-05-06 | 2005-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061419A1 true PE20061419A1 (es) | 2007-01-28 |
Family
ID=37397050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000473A PE20061419A1 (es) | 2005-05-06 | 2006-05-05 | Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090280106A1 (es) |
| EP (1) | EP1896048A4 (es) |
| JP (1) | JP2008539723A (es) |
| AR (1) | AR053263A1 (es) |
| CA (1) | CA2607273A1 (es) |
| DO (1) | DOP2006000106A (es) |
| PE (1) | PE20061419A1 (es) |
| TW (1) | TW200716156A (es) |
| UY (1) | UY29519A1 (es) |
| WO (1) | WO2006121588A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0708316A2 (pt) * | 2006-02-28 | 2011-05-24 | Lilly Co Eli | agonistas peptìdicos seletivos do receptor vpac2 |
| GB0724953D0 (en) * | 2007-12-20 | 2008-01-30 | Lytix Biopharma As | Methods of peptide modification |
| CA2779496A1 (en) * | 2009-11-02 | 2011-05-05 | The Administrators Of The Tulane Educational Fund | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| WO2012156968A2 (en) * | 2011-05-19 | 2012-11-22 | Ariel - University Research And Development Company, Ltd. | Use of mesenchymal stem cells for the improvement of affective and cognitive function |
| CN105601571B (zh) * | 2015-12-22 | 2019-03-05 | 北京医药集团有限责任公司 | 苯并咪唑类衍生物、其制备方法和应用 |
| US20220380431A1 (en) * | 2017-08-09 | 2022-12-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycopeptide analogs of secretin family peptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039111D1 (de) * | 1999-09-28 | 2008-07-17 | Bayer Corp | Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung |
| AU2002220720B2 (en) * | 2000-11-28 | 2006-09-14 | Mondobiotech Ag | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
| RU2360922C2 (ru) * | 2002-07-12 | 2009-07-10 | БАЙЕР ХелсКер ЛЛСи | Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения |
| KR20070009554A (ko) * | 2004-01-27 | 2007-01-18 | 바이엘 파마슈티칼스 코포레이션 | 뇌하수체 아데닐레이트 사이클라제 활성화 펩티드(ｐａｃａｐ) 수용체 (ｖｐａｃ２) 작용제 및 이의약리학적 사용 방법 |
| US20080026996A1 (en) * | 2004-05-21 | 2008-01-31 | Eli Lilly And Company | Selective Vpac2 Receptor Reptide Agonists |
| US20080096811A1 (en) * | 2004-05-21 | 2008-04-24 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| EP1768686A4 (en) * | 2004-06-12 | 2007-11-14 | Bayer Pharmaceuticals Corp | PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE |
| WO2006023359A2 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
-
2006
- 2006-04-18 WO PCT/US2006/014808 patent/WO2006121588A2/en not_active Ceased
- 2006-04-18 EP EP06750765A patent/EP1896048A4/en not_active Withdrawn
- 2006-04-18 JP JP2008510022A patent/JP2008539723A/ja active Pending
- 2006-04-18 US US11/919,819 patent/US20090280106A1/en not_active Abandoned
- 2006-04-18 CA CA002607273A patent/CA2607273A1/en not_active Abandoned
- 2006-05-03 AR ARP060101786A patent/AR053263A1/es not_active Application Discontinuation
- 2006-05-04 UY UY29519A patent/UY29519A1/es not_active Application Discontinuation
- 2006-05-05 DO DO2006000106A patent/DOP2006000106A/es unknown
- 2006-05-05 TW TW095115977A patent/TW200716156A/zh unknown
- 2006-05-05 PE PE2006000473A patent/PE20061419A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1896048A2 (en) | 2008-03-12 |
| UY29519A1 (es) | 2006-11-30 |
| US20090280106A1 (en) | 2009-11-12 |
| EP1896048A4 (en) | 2010-11-03 |
| TW200716156A (en) | 2007-05-01 |
| WO2006121588A3 (en) | 2007-02-15 |
| DOP2006000106A (es) | 2007-04-15 |
| JP2008539723A (ja) | 2008-11-20 |
| CA2607273A1 (en) | 2006-11-16 |
| WO2006121588A2 (en) | 2006-11-16 |
| AR053263A1 (es) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102351313B1 (ko) | Gip/glp1 공효능제 화합물 | |
| Lewis et al. | A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential | |
| EA201170337A1 (ru) | Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения | |
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| NZ597554A (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
| AR043688A1 (es) | Analogos del peptido yy | |
| JP2016512255A5 (es) | ||
| JP2013518115A5 (es) | ||
| EP1617856B1 (en) | Somatostatin-dopamine chimeric analogs | |
| AR066175A1 (es) | Ligandos del receptor de melanocortina de peptidos ciclicos | |
| RU2010153217A (ru) | Пептидные аналоги альфа-меланоцитстимулирующего гормона | |
| Křížková et al. | Insulin–insulin-like growth factors hybrids as molecular probes of hormone: receptor binding specificity | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| Lin et al. | Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors | |
| PE20061419A1 (es) | Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) | |
| WO2017178829A1 (en) | Peptide analogues | |
| AR049149A1 (es) | Analogos antagonistas de gh-rh | |
| WO2016172269A2 (en) | Insulin analogs having shortened b chain peptides and associated methods | |
| Wang et al. | Position of Pro and Ser near Glu7. 32 in the extracellular loop 3 of mammalian and nonmammalian gonadotropin-releasing hormone (GnRH) receptors is a critical determinant for differential ligand selectivity for mammalian GnRH and chicken GnRH-II | |
| US5462926A (en) | Neuromedin B receptor antagonists which demonstrate selectivity | |
| US7538185B2 (en) | Glucagon-like peptide-1 analogs with long duration of action | |
| ES2180781T3 (es) | Nuevos ligandos del receptor opiaceo mu: agonistas y antagonistas. | |
| CHOREV et al. | Effects of hydrophobic substitutions at position 18 on the potency of parathyroid hormone antagonists | |
| HUT70176A (en) | Amylin antagonists and agonists | |
| AU765512B2 (en) | Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |